Emtricitabine, commonly known by its abbreviation FTC, is a cornerstone antiviral drug used both in the treatment of HIV and in the prevention of new infections. Developed in the 1990s at Emory University, FTC belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and appears in many of the most widely prescribed HIV pill combinations worldwide. Its role has expanded considerably since its original approval for treatment, becoming a critical ingredient in pre-exposure prophylaxis (PrEP) regimens that can reduce the risk of acquiring HIV by more than 90% when taken consistently.
How FTC Works Against HIV
HIV replicates by converting its RNA into DNA using an enzyme called reverse transcriptase. FTC mimics one of the natural building blocks the virus needs for that conversion. When the enzyme incorporates FTC into the growing DNA chain instead of the real building block, the chain is cut short and the virus cannot finish making copies of itself. This “chain termination” approach is the defining feature of the NRTI drug class, which includes other medications that use the same general trick but target different nucleoside bases.
What makes FTC particularly useful is its pharmacokinetic profile. After a single oral dose, FTC stays active inside cells for a long time, with the active form persisting for roughly 39 hours. That long intracellular lifespan allows once-daily dosing with a single 200-mg capsule, which simplifies treatment considerably compared to drugs that require multiple daily doses.1PubMed. Emtricitabine: a novel nucleoside reverse transcriptase inhibitor
FTC in HIV Treatment Regimens
FTC is rarely used alone. In standard antiretroviral therapy, it serves as one part of a combination regimen, typically paired with tenofovir (in one of its two forms) plus a third drug from a different class. The goal is to attack the virus at multiple points in its lifecycle, making it much harder for HIV to develop resistance to the entire regimen at once.
Modern first-line treatment for most adults combines FTC with tenofovir and an integrase inhibitor like dolutegravir. In a large trial of pregnant women starting HIV treatment, those receiving dolutegravir-based regimens achieved viral suppression at delivery in about 98% of cases, compared with 91% among those on older efavirenz-based combinations.2The Lancet. Dolutegravir matched with tenofovir alafenamide–emtricitabine, tenofovir disoproxil fumarate–emtricitabine, or efavirenz–tenofovir disoproxil fumarate, as initial treatment for pregnant women with HIV (IMPAACT 2010) While FTC isn’t the only variable in those comparisons, its consistent presence in modern regimens reflects its reliability and tolerability as a backbone NRTI.
FTC Versus Lamivudine
FTC and lamivudine (3TC) are chemical cousins. They share the same basic structure and target the same step in viral replication. In clinical trials, FTC has shown outcomes equivalent to or slightly better than lamivudine when used as part of multi-drug regimens.3PubMed. Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor The practical advantages of FTC come down to dosing convenience and durability. FTC’s longer intracellular half-life supports reliable once-daily dosing, whereas lamivudine was historically dosed twice daily (though a once-daily lamivudine formulation exists now). There is also some evidence suggesting a decreased potential for drug resistance with FTC compared with lamivudine, though both drugs share the same primary resistance mutation.
Because of their structural similarity, the two drugs are cross-resistant: a virus that becomes resistant to one will generally be resistant to the other. This means choosing between them is more about pharmacokinetics and co-formulation convenience than about different resistance profiles.
FTC as Pre-Exposure Prophylaxis
The use of FTC that has probably reached the widest public awareness is in PrEP, where HIV-negative people take a daily pill to prevent infection. The combination of FTC with tenofovir disoproxil fumarate (TDF) was the first approved PrEP regimen, sold under the brand name Truvada. Four placebo-controlled randomized trials demonstrated that this daily combination significantly reduces HIV acquisition in men who have sex with men, heterosexual individuals at high risk, and people who inject drugs, with efficacy exceeding 90% when adherence is good.4JAMA. HIV Preexposure Prophylaxis: A Review
Adherence is the critical variable. In one clinical trial, participants with detectable tenofovir in their blood at meaningful concentrations saw protection rates of roughly 90% or higher in the FTC/TDF arm.5PubMed Central. HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention When people miss doses frequently, drug levels drop below the threshold needed for protection, and efficacy falls accordingly. This makes FTC-based PrEP unusual among prevention tools: the drug itself is highly effective, but its real-world impact depends entirely on consistent use.6PubMed Central. Maximizing the Benefits of HIV Preexposure Prophylaxis
On-Demand Dosing for PrEP
Not everyone finds a daily pill practical, and research has shown that event-driven (or “on-demand”) PrEP can work for men who have sex with men. This approach involves taking two pills before anticipated sexual contact, then one pill on each of the two following days. A French observational study found that overall HIV incidence did not differ between participants using daily PrEP and those using on-demand PrEP, with an overall rate of about 1.1 cases per 1,000 person-years.7The Lancet HIV. Daily relative to on-demand pre-exposure prophylaxis for HIV prevention among men who have sex with men in France (ANRS PREVENIR)
A Dutch cohort study echoed these findings, observing very low HIV incidence among participants who chose either daily or event-driven PrEP.8The Lancet HIV. Acquisition and cessation of sexually transmitted infections among HIV negative men who have sex with men after initiating daily and event-driven pre-exposure prophylaxis in Amsterdam, the Netherlands (AMPrEP) On-demand PrEP is currently supported primarily by evidence in men who have sex with men and has not been validated for other populations, partly because the tissue distribution of FTC matters. FTC reaches higher concentrations in vaginal and cervical tissue than in rectal tissue, but it also clears more slowly from rectal tissue, and the dosing window for on-demand use was studied specifically in the context of receptive anal sex.9PubMed Central. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission
Truvada Versus Descovy for PrEP
FTC appears in both of the oral PrEP formulations currently approved in the United States. Truvada pairs FTC with tenofovir disoproxil fumarate (TDF), while Descovy pairs FTC with tenofovir alafenamide (TAF). The difference lies in how tenofovir is delivered to the body. TAF is a newer prodrug that achieves high concentrations of the active form in target cells while exposing the kidneys and bones to less tenofovir than TDF does.
The DISCOVER trial, which enrolled over 5,000 participants, established that the TAF-based combination was non-inferior to the TDF-based combination for HIV prevention. After roughly 8,756 person-years of follow-up, seven HIV infections occurred in the TAF group versus fifteen in the TDF group. Both regimens were well tolerated, though the TAF combination was superior on all six prespecified bone and kidney safety measures.10PubMed Central. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER) For people with existing kidney concerns or low bone mineral density, the TAF formulation may be a better fit.11PubMed Central. Patient-Focused Selection of PrEP Medication for Individuals at Risk of HIV: A Narrative Review
One important caveat: the DISCOVER trial enrolled cisgender men who have sex with men and transgender women. It did not include cisgender women, so Descovy’s PrEP approval does not extend to vaginal exposure. Truvada (or its generic equivalents) remains the oral PrEP option with the broadest approved indications.
Drug Resistance and FTC
The primary resistance mutation associated with FTC is called M184V (or the related M184I variant), a change at position 184 of the reverse transcriptase gene. When this mutation emerges, it confers high-level resistance to both FTC and lamivudine.12PubMed Central. In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine Laboratory studies have shown that the M184V version produces resistance of over 1,000-fold to FTC.13JAIDS Journal of Acquired Immune Deficiency Syndromes. HIV-2 Antiviral Potency and Selection of Drug Resistance Mutations by the Integrase Strand Transfer Inhibitor Elvitegravir and NRTIs Emtricitabine and Tenofovir In Vitro
There is a silver lining. The M184V mutation actually makes HIV more susceptible to tenofovir and significantly reduces the virus’s ability to replicate. Researchers have observed that even though FTC and lamivudine lose most of their direct antiviral punch against viruses carrying this mutation, the drugs still seem to retain modest activity, possibly because the mutation hobbles the virus.14PubMed Central. Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I This is why clinicians sometimes continue FTC even when M184V is present: the crippled virus replicates more slowly and remains more vulnerable to partner drugs in the regimen.
Resistance Concerns With PrEP Specifically
One question that comes up frequently is whether widespread PrEP use could breed drug-resistant HIV on a population level. So far, the evidence is reassuring. Resistance to FTC or tenofovir from PrEP use is uncommon when PrEP is started before HIV infection has occurred.15PubMed Central. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis? The situation changes dramatically when someone starts PrEP while unknowingly already infected with HIV, particularly during acute infection when standard antibody tests may still be negative. In those cases, resistance mutations are much more likely to be selected because the virus is replicating freely against only two drugs rather than the three-drug regimen used for treatment.16PubMed Central. How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?
When PrEP-associated resistance has been detected, it tends to fade relatively quickly after the drug is stopped.17PubMed Central. PrEP-selected Drug Resistance Decays Rapidly After Drug Cessation This is partly because viruses carrying M184V replicate less efficiently than wild-type virus, so once FTC is removed, the resistant population gets outcompeted. The practical takeaway is that HIV testing before starting PrEP and at regular intervals while on PrEP is essential, not optional.
Side Effects and Tolerability
FTC is generally well tolerated, which is a major reason it has remained a preferred NRTI for over two decades. The most common side effects reported in clinical trials include headache, nausea, and diarrhea, but these are usually mild and tend to improve after the first few weeks. The serious side effects associated with FTC-containing regimens tend to be driven by tenofovir (the partner drug) rather than by FTC itself, particularly the kidney and bone concerns linked to TDF.
One unusual side effect is skin hyperpigmentation. A Japanese study found that about 4% of patients developed small dark spots, mostly on the palms or soles, within the first year of FTC use. The spots were mild, typically just 1 to 2 mm across, and they faded or disappeared over a few months even when FTC was continued.18PubMed. Investigation of emtricitabine-associated skin pigmentation and safety in HIV-1-infected Japanese patients This effect appears to be more common in people with darker skin tones and is thought to be related to the fluorine atom in FTC’s chemical structure.
FTC During Pregnancy
Preventing mother-to-child HIV transmission is one of the great success stories of antiretroviral therapy, and FTC-containing regimens play a central role. Pregnancy does alter FTC’s pharmacokinetics: drug exposure drops modestly compared to the postpartum period because of the increased blood volume and kidney clearance that occur during pregnancy. However, the decrease is less than 20%, and drug concentrations remain above the level needed to suppress the virus in all study participants. Dose adjustment during pregnancy is not considered necessary.19PubMed Central. Effect of pregnancy on emtricitabine pharmacokinetics
FTC crosses the placenta well, providing antiviral concentrations in the newborn at birth that help protect against transmission.20PubMed Central. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants Current evidence from clinical trials supports the use of dolutegravir combined with FTC and tenofovir alafenamide as a preferred regimen when antiretroviral therapy is initiated during pregnancy.21The Lancet HIV. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED)
FTC in Post-Exposure Prophylaxis
Beyond PrEP and treatment, FTC also appears in post-exposure prophylaxis (PEP) regimens, which are taken after a potential HIV exposure. PEP typically involves a 28-day course of three antiretroviral drugs started as soon as possible (ideally within 72 hours) after exposure. The combination of raltegravir with tenofovir and FTC has been evaluated as a PEP regimen and was found to be tolerable, which matters because a month of medication is a commitment and side effects can undermine completion rates.22JAIDS Journal of Acquired Immune Deficiency Syndromes. Raltegravir, Tenofovir DF, and Emtricitabine for Postexposure Prophylaxis to Prevent the Sexual Transmission of HIV Current guidelines in most countries include FTC/tenofovir as the backbone of recommended PEP regimens.
Drug Interactions
One of FTC’s practical strengths is its limited drug interaction profile. Unlike some antiretrovirals that are metabolized through liver enzyme pathways (making them prone to interactions with dozens of other medications), FTC is primarily cleared by the kidneys. Research has shown that FTC is a substrate of a specific kidney transporter called MATE1. When other drugs that inhibit this transporter are co-administered, they can decrease the kidney’s ability to clear FTC and increase its concentration inside cells. In laboratory studies, cimetidine and ritonavir each reduced MATE1-mediated transport of FTC by roughly 40%.23PubMed. Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters In practice, this interaction is managed within HIV treatment itself, since ritonavir is a common booster in certain regimens and clinicians are aware of its effects.
For most people, the simplicity of FTC’s metabolism means they can take other common medications without worrying about interactions that would change FTC’s effectiveness or safety. This is a meaningful advantage over drugs that pass through liver pathways, where interactions with antidepressants, antifungals, birth control pills, and many other medications can become complicated.
Barriers to PrEP Access and Adherence
Having a highly effective drug is one thing; getting it to the people who need it is another. An integrative review of barriers to PrEP use found that over 60% of studies identified social barriers, including stigma related to sexuality and HIV, as major obstacles. Individual-level barriers like alcohol use, worries about side effects, and concerns about long-term toxicity also featured prominently.24Revista Brasileira de Enfermagem. Barriers to Pre-Exposure Prophylaxis use for HIV: an integrative review
Cost has historically been a substantial barrier in many countries. In the United States, the branded combination of TDF/FTC was priced at over $21,000 per person per year before generic versions became available, compared with a minimum generic price of around $67 per person per year.25PubMed Central. How can we achieve universal access to low-cost treatment for HIV? The availability of generics has dramatically changed the landscape in low- and middle-income countries, where FTC-containing regimens are now part of standard national treatment and prevention programs. In the United States, multiple generic versions of Truvada reached the market after patent expiration, and federal programs now cover PrEP at no cost for many insured individuals, though navigating coverage remains a challenge for some.
The Discovery of FTC
FTC’s origin story begins in 1990 at Emory University, where Dennis Liotta’s research group developed a synthesis of compounds related to cytidine, one of the nucleoside building blocks of DNA. They found that certain modified versions had potent anti-HIV activity without apparent toxicity to human cells. When the researchers separated the mirror-image forms of the molecule, the “minus” enantiomer showed an especially attractive profile, and that molecule became FTC. Triangle Pharmaceuticals licensed FTC from Emory in 1996 and moved it into clinical trials.26PubMed Central. Discovery and Development of the Anti-Human Immunodeficiency Virus Drug, Emtricitabine (Emtriva, FTC) Gilead Sciences later acquired Triangle and brought FTC to market as Emtriva in 2003, then combined it with tenofovir to create Truvada in 2004. That combination went on to become the backbone of PrEP when the FDA approved it for prevention in 2012, transforming FTC from a treatment drug into one of the most widely discussed tools in public health.